Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_assertion description "[Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_assertion evidence source_evidence_literature NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_assertion SIO_000772 15543614 NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_assertion wasDerivedFrom befree-20150227 NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_assertion wasGeneratedBy ECO_0000203 NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.
- befree-20150227 importedOn "2015-02-27" NP628369.RAb4DoGQZAskeTR4mdRHoWmB3BlP7T6ktNfv-89YtSs_Y130_provenance.